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Clearcellsarcomasareaggressive,raresofttissuetumorsandtheirclassiﬁcationamongmelanomaorsarcomaisstillundetermined
due to their clinical, pathologic, and molecular properties found in both types of tumors. This is a retrospective study of 52
patients with CCS seen between April 1979 and April 2005 in two institutions. The EWS-ATF-1 fusion transcript was studied
in 31 patients and an activating mutation of the BRAF or NRAS gene was researched in 22 patients. 30 men and 22 women,
with a mean age of 33 were studied. Forty-three tumors (82.69%) were located in the extremities, specially the foot (19 tumors).
Median initial tumor size was 4.8cm (1 to 15cm). Necrosis involving more than 50% of the tumor cells was found in 14 cases
(26.92%). High mitotic rate (>10) was found in 25 cases (48.07%). The EWS/ATF-1 translocation was found in 28 (53.84%) of 31
patients studied, and mutation of BRAF or NRAS was found in only 2 of 22 patients analyzed cases (3.84%). Among the tumor-
associated parameters, only tumor size (>4cm) emerged as a signiﬁcant prognostic factor. Forty-nine patients had a localized
disease at diagnosis (94.23%) and underwent surgical resection immediately (90%) or after neoadjuvant chemotherapy (CT)
(10%). Various CT regimens were used in 37 patients (71.15%) with no signiﬁcant eﬃcacy. The 5- and 10-year OS rates were 59%
and 41%, respectively. Tumor size was the only emerging prognosis factor in our series. Complete surgical resection remains the
optimal treatment for this aggressive chemoresistant tumor.
1.Introduction
C l e a rc e l ls a r c o m a( C C S )i sar a r em a l i g n a n tt u m o rt h a tw a s
describedﬁrstbyEnzingerin1965[1].CCSshowsapredilec-
tion for the deep soft tissues of the lower extremities close to
thetendon,fascia,oraponeuroses[2].Itoccurspreferentially
in adolescents and young adults and is associated with a
high propensity of local recurrence, regional lymph node
metastases, and distant metastases [1, 2]. Because of its close
clinicandhistologickinshipwithmalignantmelanoma(high
frequency of lymph node metastases, presence of melanin,
ultrastructural evidence of melanosomes, and immuno-
histochemical staining for S-100 protein and melanoma-
associated antigen HMB-45), Chung and Enzinger proposed
the name malignant melanoma of soft parts [2]. However,
despite these similarities, CCS and melanoma should be
considered 2 distinct entities. Unlike melanomas, most
CCS tumors are characterized by a recurrent chromosomal
translocation, t(12; 22), resulting in fusion of the EWS gene
on 22q12 with the ATF1 gene on 12q13 [3]. Several fusion
transcript types have been described, with a predominance
o ft y p e1f u s i n ge x o n8o fE W Sw i t he x o n4o fA T F 1a n d
t y p e2f u s i n ge x o n7o fE W Sw i t he x o n5o fA T F 1[ 4].
The prevalence of t(12; 22) fusion transcripts detected by
moleculartechniqueshasbeenreportedinonly3smallseries
of 10 patients, 12 patients, and 9 patient with CCS [3–5].
High incidence of activating mutations in the BRAF gene
has been reported in melanoma cell lines, melanoma short-
term cultures, primary and metastatic melanomas, and nevi
[6]. All the mutations were detected in the kinase domain2 Dermatology Research and Practice
of the BRAF gene and found in exons 11 and 15. The
most common mutation (V599E) is the T1796A single-base
substitution in exon 15, leading to an exchange of valine for
glutamic acid at position 599 [6].
This mutation was not reported in soft tissue sarcomas
including a small series of 8 CCS [4]. Compared with the
extensive literature regarding the histopathologic nature of
the disease, very little is known about the clinical and
molecular features of CCS. The main obstacle to gaining a
thoroughunderstandingoftheclinicalandmolecularbehav-
ior of CCS is the rarity of the disease.
We describe the clinicopathological data of 52 patients
with clear cell sarcoma with emphasis on prognostic factors
and treatment outcomes. Mutational status on BRAF, NRAS
gene, and cytogenetic study of translocation (12, 22) (q13,
q12) were also studied (Table 1).
2. Patientsand Methods
Between April 1979 and April 2005, 52 consecutive cases
of CCS were registered at the Gustave Roussy, Villejuif (46
patients) and Bergonie, Bordeaux (6 patients) institutes.
Completeinformationonclinicaldata,treatmentmodal-
ities, and outcome was reviewed in all cases to exclude an
antecedent or a concurrent diagnosis of primary cutaneous
melanoma. When the initial biopsies were done outside the
institutes, the histopathologic diagnosis was conﬁrmed by
Gustave Roussy or Bergonie Institute expert of pathologists.
Histologic criteria for the diagnosis of CCS are the intimate
association of small solid aggregates of round-to-fusiform,
pale-staining cells within the dense connective tissue of ten-
dons and aponeuroses, the ﬁne reticular stroma surrounding
the cells, the relative uniformity of cells showing abundant
clear cytoplasm, and scattered multinucleated giant cells.
Mitotic ﬁgures are generally infrequent. A conﬁrmation
of diagnosis is obtained by immunohistochemistry with a
diﬀuse or focal positivity for S-100 protein and melanocyte-
associated antigen HMB-45, positivity for neuron-speciﬁc
enolase (NSE). Thirty-one cases were examined for the
presence of EWS/ATF1 transcripts by real-time PCR on
paraﬃn-embedded tissues and frozen samples.
DNA was prepared from paraﬃn-embedded tissues of 22
CCS (16 cases from GRI, 6 cases from BI) carrying the t(12;
22) translocation. PCR ampliﬁcation of BRAF exons 11 and
15aswellasNRAScodons12,13,and61wasperformed,and
P C Rp r o d u c t sw e r es e q u e n c e d .
The following demographic and treatment factors were
examined for prognostic importance: patient age (≤30
years, >30 years), sex, tumor size (≤4cm,>4cm), location,
symptoms, clinical staging, microscopic surgical margin,
chemotherapyandradiotherapy,mitoticrate(>2per10high
power ﬁelds after examining and averaging data from 20
HPF), and presence of necrosis.
With respect to tumor location, proximal sites included
the trunk and proximal extremities (upper arm and thigh),
and distal sites included distal extremities (below or at
the elbow and below or at the knee joint). The micro-
scopic surgical margin was determined histologically on the
resected specimens and was classiﬁed as negative (no tumor
cells at the inked margin) or positive (tumor cells at the
inked margin). Patients received multimodality treatment,
including surgery, radiotherapy, and chemotherapy. Wide
excision of the primary tumor with a negative surgical
margin was attempted whenever possible. If necessary,
amputation/disarticulation was planned to achieve a nega-
tive surgical margin.
All time-to-event endpoints were computed by using the
kaplan-Meier method [7].
Patients who died of causes unrelated to CCS were
censored at time of death. Potential prognosis factors were
identiﬁed by univariate analysis using the log-rank test.
Independent prognostic factors were evaluated with Cox
proportional-hazards regression using a stepwise selection
procedure [8]. To arrive at a parsimonious multivariate
model, covariates were selected into the model only if they
contributedsigniﬁcantlytotheﬁtofthemodel.Thecriterion
used to select covariates into the model was the score chi-
square statistic. Diﬀerences at P<. 05 were considered
signiﬁcant. Statistical analyses were performed using the
StatView 5 statistical package.
3. Results
The study group comprised 30 men (57.69%) and 22 women
(42.30%), and patients ranged in age from 6 years to 81 years
(median, 33 years). Forty-two percent of patients were aged
≤30 years, and 94% were aged <60 years.
Forty-three tumors (82.69%) were located in the extrem-
ities, eight tumors (15.38%) were located in the trunk, and
one tumor was located in the scalp. The most common
tumor site was the foot (19 tumors), followed by the
hand (13 tumors), and the thigh (9 tumors). Fourteen
tumors (26.92%) were considered proximal, and 38 tumors
(73.07%) were considered distal.
Fifty patients (96.15%) had a mass that had been enlarg-
ing slowly for periods ranging from six weeks to four years
(median, 15 weeks). Pain and/or tenderness were observed
in 30 patients (57.69%), and this was frequently the main
reason for seeking medical advice. In two patients, acute
urinary retention wastheﬁrstsignofthe disease.No patients
had a history of melanoma or unusual pigmented skin
lesions.
At presentation the malignant nature of the swelling
was seldom suspected, and in thirty-six patients (69.23%),
a biopsy was performed. Nevertheless in sixteen patients
(30.76%), the lesion was thought to be benign on clinical
grounds, and initial clinical diagnosis included epithelial cyst
(7 patients) exostose (4 patients), haematoma (2 patients),
and neurinoma, lipoma, and carpal tunnel syndrome (1
patient each).
Initial diagnosis was made at another institution in all
cases, with incisional or excisional biopsy. All cases were
reviewedbytheGustaveRoussyortheBergonieInstitute soft
tissue pathologists.
The tumors ranged in size from 1cm to 15cm (median,
4, 86cm). The tumors measured <4cm in 30 patientsDermatology Research and Practice 3
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(57.69%) and between 4cm and 15cm in 21 patients
(40.38%). Tumor size was unknown in one patient.
In all cases, the tumor cells were arranged in nests, clefts,
and an alveolar pattern, separated by ﬁbrous septa. Some
dyscohesive cells were seen lying in spaces. The cells showed
necrosis less than 50% in 33 patients (63.46%), more than
50%in14patients(26.92%),andnoevidenceofnecrosisin5
patients (09.61%). Of the fourteen patients whohad necrosis
more than 50%, ten patients died. The number of mitoses
waslessthan10perhighpo werﬁelds(10HPF)in27patients
(51.92%), between 10 and 20 per 10 HPF in 21 patients
(40.38%), and more than 20 per HPF in 4 patients (7.69%).
Forty tumors (76.92%) were grade 2, and twelve tumors
(23.07%) were grade 3 using the FNCLCC grading system.
HMB45 was diﬀusely positive in forty-four tumors
(84.61%) and focally positive in 8 patients (15.38%). S100
protein was largely positive in forty-four patients (84.61%),
focally positive in 5 cases (09.61%), and negative in 3 cases
( 5 . 7 6 % ) .M e l a nAa n dM I T Fw e r ee x p r e s s e di nm a n yc a s e s
(76.92% and 84.6% of cases, resp.) including S100 protein-
negative tumors. Vimentin could be detected in 3 cases
(5.76%). None of our cases had expressions of keratin.
Only one of the 22 CCS harboured a BRAF mutation
(V599E); it was the well-known valine to glutamic acid
change in position 599. No exon 11 mutation were found.
One mutation of NRAS (codon 61) was also found with no
overlap with the BRAF mutation. The EWS/ATF-1 fusion
transcript was detected in 28 patients of the 31 paraﬃn-
embedded CCS, and 3 of the 31 patients were negative. The
two tumours that presented a BRAF or NRAS mutation also
presented the ATF1-EWS fusion gene and were considered
atypical. However, the absence of cutaneous involvement,
histologic features (spindle and a few epithelioid cells
arranged in a nested pattern), and immunohistochemistry
(diﬀuse positivity for S100 protein and HMB45) strongly
suggested a diagnosis of CCS.
Forty-nine patients (94.23%) presented with localized
disease; forty-four patients (84.61%) of them underwent
surgical resection of primary tumor. Nineteen patients
(36.53%) underwent complete surgical resection with neg-
ative margins; twenty-ﬁve patients (48.07%) had residual
microscopic disease and underwent adjuvant therapy espe-
cially radiotherapy.
The last ﬁve patients with localized disease received
neoadjuvantchemotherapybeforesurgicalresectioninorder
to reduce tumors size and make surgical resection possible.
Two patients (3.84%) presented with disease metastatic
to lymph nodes. One patient presented with disease me-
tastatic to both lymph nodes and lung.
Deﬁnitive surgicalmanagementincluded widelocalexci-
sions in 29 patients, local excision in 11 patients, radical
compartment resection in 4 patients, and amputation in 3
patients. Adjuvant treatment was given to 42 patients and
consisted of radiotherapy in 40 patients (76.92%) with
a median of 50 grays. This radiotherapy was associated
to adjuvant chemotherapy in 10 patients, and 2 patients
received adjuvant chemotherapy alone.
patients (55, 76%) developed local recurrence. The time
interval from initial treatment to local relapses ranged from
1 month to 20 years, with a median of 38 months. Local
recurrence was seen in 55% of the 29 patients at 5 years and
63% at 10 years. Sixteen of these patients received additional
surgical treatment and 3 had amputation. Of the other 10
patients (19.23%), they were already known to have regional
lymph node metastases and/or had disseminated disease.
Of the 29 patients (55, 76%) who had local recurrences, 19
(36.53%) died of the tumors, three (5.76%) are alive with
disease, but only seven (13.46%) patients are alive free of
disease.
No local recurrences occurred in 23 patients (44.23%)
who had surgical resection with negative margins (16
patients) or with positive margins associated to adjuvant
radiotherapy (7 patients). The overall survival rate without
local recurrence was 30% at 5 years and 16% at 10
years.
Nineteenpatientsdevelopedregionallymphnodemetas-
tases at 5 years in 34% and at 10 years in 41% of them.
Of these patients, six (11.53%) had lymph node metastases
withinlessthan1yearofthefollowup,threepatients(5.76%)
between 1 and 2 years, and 10 patients (19.23%) between 2
and 7 years of the followup. Regional lymph node dissection
was performed on fourteen patients and was associated with
regional isolated limb perfusion with melphalan and tumor
necrosis factor alpha in one case. Five patients had already
distant metastases.
Thirty patients developed distant metastases: 43% of
them at 5 years and 62% at 10 years. Of them, twenty-
seven patients died because of disease and three are alive
with disease (time of followup: 09, 63, 84 months). Distant
metastases most frequently involved the lungs (27 patients),
bones (2 patients), and distant lymph nodes (1 patient).
Twenty-four patients received some form of chemother-
apy, and three patients had surgical treatment (accessible
metastases sites and single localisation).
Various chemotherapeutic regimens for musculoskeletal
sarcomas or for malignant melanoma, in adjuvant aim or
in curative one, were employed, including actinomycin,
Adriblastina, cyclophosphamide, carboplatine, cisplatine;
dacarbazine, etoposide, fotemustine; iosfamide, interleukin
2, ifosfamide (3g/m2) + dactinomycin (1,5mg/m2)+
vincristine (1,5mg/m2); regional isolated limb perfu-
sion with melphalan and tumor necrosis factor alpha,
methotrexate, MAID: doxorubicine (15mg/m2)+d a c a r -
bazine (250mg/m2/j) + ifosfamide (2–2,85g/m2/j), vin-
cristine; VACA: cyclophosphamide (1,2g/m2)+d o x o r u -
bicine(30mg/m2)+dactinomycin(0,5mg/m2)+vincristine
1,5mg/m2; intrferon and taxol.
In twenty-one patients, chemotherapy was discontinued,
usually after three courses, because of tumor progression
(18 patients) or major hematotoxicity (3 patients). Local
radiotherapy for distant metastases sometimes brieﬂy allevi-
ated the pain and was mostly given to patients with skeletal
metastases.
The overall survival rate was 59% at 5 years and 41%
at 10 years (Figure 1). Median time of follow up was 120
months (11–348). On multivariate analysis, only tumor size
(P :0 .01) emerged as a signiﬁcant prognostic factor (Table 2
and Figure 2).6 Dermatology Research and Practice
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Figure 1: Overall survival of 52 patients with clear cell sarcoma.
Table 2: Multivariate analysis of overall survival.
Variable Number 5-year survival
univariate P
Event-free
Survival
Sex
Men 30 0,83 0,70
Women 22
Age
≤30y 22 0,32 0,38
>30y 30
Size
≤4cm 30 0,06 0,01
>4cm 21
Mitoses
<10 27 0,61 0,44
≥10 25
Necrosis
<50% 38 0,66 0,47
≥50% 14
Grade
2 40 0,19 0,16
31 2
4. Discussion
These results conﬁrmed the known clinical features of
CCS originally reported by Enzinger [1]: arising primarily
in young adults, predominance in distal extremities, and
presenting as a slowly enlarging mass that has been evident
for several months or even years. The principal sites of the
neoplasm are the extremities, especially the region of the
foot and ankle. The head, neck, and trunk regions are only
rarely involved. In our study, forty-three tumors (82.69%)
were located in the extremities. The most common tumor
site was the foot (19 tumors). Fourteen tumors (26.92%)
were considered proximal, and 38 tumors (73.07%) were
considered distal. Our ﬁndings also revealed several impor-
tant factors that predict the clinical behavior of CCS and
disclosed problems awaiting solution.
0
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0.8
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Size <= 4
Size > 4
Risk
30 27 22 15 15 12 7 6 4 4 4 4 4 2 1 1
2 1 1 4 865432211
Event-free survival
log rank P = 0.01
Figure 2: Event-free survival of 52 patients with clear cell sarcoma
according to tumor size (P = 0.01).
Over half of all clear cell sarcoma reported in the
literature measured less than 4cm [2], a ﬁnding in accord
with our series in which 57.69% of patients had lesions that
measured less or equal to 4cm. CCS mainly aﬄicts young
adults between the ages of 20 to 40 years [4, 5], but in
rare instances it may occur in the extremes of ages. In our
study, the mean age was 33 and 26 years (range 6–81 years).
Although some reports have found predominance in females
[6], the gender distribution between males and females is
equal [2]. CCS was slightly more common in male than fe-
male patients in our series.
CCS is characterized by a recurrent chromosomal trans-
location t(12; 22), which results in fusion of the EWS gene
on 22q with the ATF1 gene on 12q [4]. This genomic abnor-
mality may represent a good marker for identifying these
tumors. In the current study, 90.32% of the analyzed tumors
(28 of 31 tumors) had this translocation.
As previous studies [4–7], our data further suggests that
CCS and conventional melanoma develop through diﬀer-
ent genetic pathways. Indeed, CCS is a sarcoma subtype,
and the characteristic EWS/ATF1 translocation, resulting
in the chimeric protein EWS/ATF1, is responsible for the
melanocytic diﬀerentiation. EWS/ATF1 can bind the tran-
scription factor MITF which in turn can lead to melanocytic
diﬀerentiation with expression of the protein involved in
melanin synthesis: tyrosinase, melanin, HMB45. Because of
the extensive clinical, histologic, and immunohistochemical
similarities with melanoma, we decided to analyze whether
CCS also has mutations in the BRAF and NRAS gene. No
mutation of the BRAF nor NRAS gene was identiﬁed in
95.54% of the analyzed tumors (21 of 22 tumors). The
two tumours which were found to harbor mutations in the
BRAF and NRAS gene also presented the ATF1-EWS fusion
gene and were considered atypical. However, the absence
of cutaneous involvement, histologic features (spindle and
a few epithelioid cells arranged in a nested pattern), andDermatology Research and Practice 7
immunohistochemistry (diﬀuse positivity for S100 protein
and HMB45) strongly suggested a diagnosis of CCS.
Therefore, we support the hypothesis that CCS belongs
to the soft tissue sarcoma family and that the melanin
synthesis is due to the speciﬁc action of the chimeric
EWF/ATF1 protein via MITF activation. Molecular genetic
abnormalities have been reported in 3 small series of CCS
involving 10 patients, 12 patients, and 9 patients [3–5].
To our knowledge, the current study represents the largest
reported series of patients with CCS with emphasis on
mutational statue on BRAF, NRAS gene, and cytogenetic
study of translocation (12, 22) (q13, q12).
Size constituted the only criterion that was useful as a
predictor of the biologic behaviour of CCS (Table 3). In our
series, on multivariate analysis, only tumor size (P :0 .01)
emerged as a signiﬁcant prognostic factor.
Tumor necrosis was also a signiﬁcant indicator of poor
prognosis, independent of tumor size [11, 12]. Indeed, we
foundthatthepresenceofnecrosismorethan50%associated
with worse outcome. Of fourteen patients who had necrosis
more than 50%, ten patients died, but on multivariate
analysis, it was not a signiﬁcant prognostic factor.
Unlike most soft tissue sarcomas, CCS often metastasizes
to regional lymph nodes [1, 2]. Sixteen of our patients had
lymph node metastases. A marked tendency for regional
lymph node metastases has been observed by other authors,
Chung and Enzinger reported a 53% rate, and Eckardt et
al. [18] a 33% rate of lymph node metastases. Although we
foundlymphnodemetastasestobeslightlylessfrequentthan
pulmonary metastases, they tended to occur earlier in the
courseofthedisease.Theroleofregionallymphnodedissec-
tion in CCS has not been established to date. Some authors
recommend prophylactic elective lymph node dissection,
whereas others suggest lymphadenectomy only in patients
who show clinical lymphadenopathy [19]. Sentinel lymph
node biopsy, which has been used successfully for the staging
ofpatientswithbreastcancerandmelanoma,mayallowearly
detection of lymph node metastasis in patients with CCS
[19, 20]. It is quite possible that, with diligent staging using
sentinel node biopsy, some patients who are believed to have
localizeddiseaseinthecurrentserieswillturnoutnottohave
localized disease, and this would have a signiﬁcant impact
on the analyses. Further investigations of the usefulness of
sentinel lymph node biopsy in CCS are warranted.
Complete excision of the primary tumors appears to
be the optimal approach to treatment, a conclusion that is
sharedbyothers[15].Ofthe29patientswhohadlocalrecur-
rences, 19 died of the tumors and 3 are alive with disease.
These results suggest that local recurrence has a negative
role in the management of CCS. In our series, successful
treatment was best accomplished by excision with a wide
surgical margin, with or without adjuvant radiation therapy.
The presence of metastases, either at initial diagnosis or later
in courses of the disease, was an ominous factor; no patients
survived free of disease once metastatic CCS occurred.
The overall prognosis for CCS is poor [1–3]. In most
cases, the disease pursues a relentlessly progressive course
and terminates in death due to wide-spread dissemination.
Althoughrapidlyfatalprogressionmayoccur,latemetastases
Table 3: Clinicopathologic studies of clear cell sarcoma.
Reference Year No. of
patients
Five-year
survival
Prognostic
factors
Sara et al. [9] 1990 17 40 Size
El-Naggar et al.
[10] 1991 11 NA DNA content
Lucas et al. [11] 1992 35 67 Size, necrosis
Montgomery et
al. [12] 1993 58 63 Size∗,n e c r o s i s ∗
Deenik et al.
[13] 1999 30 30 Size,
radiotherapy
Finley et al. [14] 2001 8 55 Size
Ferrari et al.
[15] 2002 28 66 Size, site, IRS
group
Takahira et al.
[16] 2004 14 33 Mitosis
Kawai et al. [17] 2007 75 47 Size,∗ depth, sex,
TNM
Current study 2005 52 59 stage, surgical
margin size∗
NA indicates not available; IRS group, Intergroup Rhabdomyosarcoma
Study Group.
∗Multivariate analysis.
are quite common after many years of freedom from disease.
In our series, the 5-year survival was 59% at 5 years and
41% at 10 years. Similar ﬁndings have been reported in the
literature (Table 3), with local recurrence or metastases (or
both) occurring as late as 29 years after the initial surgery
[2, 15]. Thus, once a diagnosis of CCS is made, the patient is
at risk for recurrent disease for many years and must be fol-
lowed closely. Awareness of delayed progression is especially
important considering the young age of the most patients.
Therarityofthediseasemakesitdiﬃculttodrawconclu-
sive statements, but clear cell sarcoma shares many features
with melanoma, including histological, immunophenotypic,
ultrastructural, and similarities in gene expression patterns.
However, clear cell sarcoma is genetically distinct lacking
melanoma-associated BRAF mutations and instead harbor-
ing recurrent and characteristic chromosomal translocations
involving the EWSR1 gene. Although the term malignant
melanoma of soft parts persist, it is important that this
lesion be loosely considered a MM, but rather segregated as
a unique tumor of soft tissue.
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